• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IMU
Click for more information
5.41% 3.9¢

IMUGENE LIMITED - Charts / Financials

Market Cap $386.7M  ! watchlist Created with Sketch. Add to my watchlist

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing... Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs. More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 14.35pm 22/11/2024 (20 minute delay) ?
Day
Open 3.6¢   Day High 3.9¢   Day Low 3.5¢
Daily Volume 22882702
Bids   Sellers
Number Price Volume   Number Price Volume
17 3.8¢ 438995   29 3.9¢ 4266212

Directors & Senior Management

Mr. Paul E. Hopper Executive Chairman of the Board
Ms. Leslie Chong Chief Executive Officer, Managing Director, Executive Director
Mr. Michael Tonroe Chief Financial Officer, Company Secretary
Dr. Bradley Glover Chief Operating Officer
Dr. Nicholas Ede Chief Technology Officer
Dr. Monil Shah Chief Business Officer
Dr. Paul Woodard Chief Medical Officer
Ms. Kimberlee Cobleigh Drapkin Non-Executive Independent Director
Dr. Jakob Dupont Non-Executive Independent Director
Dr. Jens W. Eckstein Non-Executive Independent Director
Dr. Lesley Russell Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
3.9¢ 		Change
0.002(5.41%) 		Mkt cap ! $386.7M
Open High Low Value Volume
3.6¢ 3.9¢ 3.5¢ $836.3K 22.88M

Buyers (Bids)

No. Vol. Price($)
17 438995 3.8¢
 

Sellers (Offers)

Price($) Vol. No.
3.9¢ 4266212 29
View Market Depth
Last trade - 14.20pm 22/11/2024 (20 minute delay) ?
Last
3.9¢ 		  Change
0.002 ( 5.41 %)
Open High Low Volume
3.6¢ 3.9¢ 3.6¢ 11092999
Last updated 14.35pm 22/11/2024 ?

Top Stories

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Sales growth pushes Lovisa's fortunes (and shares) upwards Lovisa Holdings Ltd has seen its shares rise more than 2% following a sales update, and on a good day for the consumer discretionary sector
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.